Abstract
Introduction Disorders of sex development (DSDs) were defined as congenital conditions in which the development of chromosomal, gonadal and anatomic sex is atypical. Nuclear receptor subfamily 5 group A member 1 (NR5A1), previously known as steroidogenic factor 1 (SF1) plays a crucial role in transcriptional regulation of genes involved in steroidogenesis, adrenal and gonadal development, and reproduction. NR5A1 emerged to be causative of 10 to 20% of 46,XY DSD.
Objective The present study aims to perform a systematic review evaluating the association between phenotype and genotype in patients with NR5A1 defects and 46,XY DSD looking for outcomes of spontaneous puberty, change of gender and social sex.
Method The proposed systematic review will be conducted in accordance with the Joanna Briggs Institute methodology for systematic reviews of etiology and risk. This review will consider observational studies, including prospective and retrospective cohort studies, cross sectional, case series and case reports studies. We will focus on studies that included patients with allelic variants in the NR5A1 gene and 46,XY DSD. This review will consider studies that include the outcomes of spontaneous puberty, gender change and genotype/phenotype correlation associating the types of variants with the degree of external genitalia virilization.
Conclusion Results of this review can help in the management and clinical understanding of patients with NR5A1 defects and 46,XY DSD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Vania and Berenice share the last autorship
Data Availability
All data produced in the present work are contained in the manuscript
